Understanding_the_impact_of_praziquantel_treatment_on_schistosome_infrapopulations-sc-5580
Understanding_the_impact_of_praziquantel_treatment_on_schistosome_infrapopulations
It is unclear how long-term mass drug administration (MDA) programs have affected schistosome populations and there is a particular interest in the potential evolution of tolerance to praziquantel, the only drug effective against all species of schistosome parasites and the only drug used in large-scale mass drug administration programmes against the parasite. Previous studies have identified some genome regions under strong selection and associated with poor clearance of parasites (reduced egg reduction rate) following treatment with praziquantel. However, individual variants are only borderline significant when corrected for multiple testing.    This study involved whole-genome sequencing of miracidial (larval stage) isolates sampled from patients before and after they received praziquantel treatment. These isolates come from regions which have been the subject of long-term 5-8 years MDA programs. By sequencing all available miracidia from 3 patients, it will be possible to reconstruct the pedigree relating these larvae, understanding the number of adult worms contributing to these larvae, and demonstrate whether particular adult worms survive treatment in those patients that do not respond well to drug treatment. These data will allow us to perform analyses of recent evolution in these populations potentially revealing patterns of variation associated with praziquantel exposure. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
Whole-genome sequencing of miracidial (larval stage) isolates sampled from patients before and after praziquantel treatment, to better understand recent evolution in MDA exposed populations of Schistosoma mansoni.